Consensus statement for autoimmune haemolytic anaemia released

4 minute read


Guidance on how to diagnose and manage the rare condition in Australia and New Zealand is now available.


A team of Australian and New Zealand haematologists have released a set of consensus guidelines regarding the investigation and management of autoimmune haemolytic anaemia.  

“Autoimmune haemolytic anaemia is a rare immune-mediated disorder leading to accelerated red cell destruction and anaemia. There is considerable clinical heterogeneity, with some patients barely requiring intervention, while others experience fulminant haemolysis and experience mortality rates as high as 30% with severe anaemia and end-organ ischemia,” the authors wrote in the Internal Medicine Journal.  

“As there is insufficient high-quality clinical data to guide management, we developed consensus practice statements based on Delphi methodology to provide clinicians with guidelines to approach diagnostic investigations, initiation of therapy, second-line treatment options, supportive care and pregnant patients.” 

Recommendations graded by strength (either strong or weak) and the level of evidence supporting them (ranging from high-quality meta-analyses through to an expert panel consensus).  

The expert panel agreed that initial clinical investigations should assess for precipitating events, including recent infections, new medications, autoimmune conditions, or lymphoproliferative disorders.  

Family history can rule out the presence of inherited non-immune haemolytic conditions (e.g., hereditary spherocytosis), while a physical exam can determine the presence of hepatosplenomegaly and/or lymphadenopathy.  

Various laboratory tests are involved in the diagnostic process to confirm autoimmune haemolytic anaemia while ruling out other potential causes, including a peripheral blood smear, the direct antiglobulin test using semi-automated column agglutination (to confirm the immune aetiology), thermal amplitude testing, and the Donath-Landsteiner test. The authors did not recommend undertaking a routine bone marrow biopsy unless there were clinical or laboratory features that suggested a lymphoproliferative disorder.   

Recommendations for management were made for warm AIHA, with the authors emphasising that the goal of treatment should be the resolution of symptomatic anaemia with transfusion independence. As a starting point, patients should receive 5mg of folic acid daily to account for the increased demands on the body while it remained in a phase of compensatory erythropoiesis.  

Corticosteroids – specifically 1mg/kg/day of prednisolone – were recommended as the standard first-line therapy for a period of two to three weeks before tapering once haemolysis has significantly reduced and haemoglobin levels are stable.  

Rituximab could also be used as a first-line therapy in combination with prednisolone or added as a second-line therapy in patients who displayed little to no response to corticosteroids after two weeks.  

Splenectomy should be avoided in patients aged ≥65 years or in patients with an elevated risk of thrombosis, cardiopulmonary disease, underlying immunodeficiency, lymphoproliferative disease, or other autoimmune conditions. 

The authors noted that red cell transfusions could offer significant benefit to patients who present with fulminant haemolysis but that “the inherent risks of transfusing red cells with various levels of crossmatching into patients with active immune-mediated haemolysis must be balanced against the clinical urgency to restore the metabolic requirements for oxygenation”.  

Specific recommendations were made for pregnant patients with warm AIHA, despite the rareness of the condition (as few as one in 140,000 pregnancies).  

“All pregnant patients with wAIHA must be reminded to take high-dose folate supplementation 5mg daily rather than the standard maternal health dose of 500–800mcg,” wrote the authors. 

“They should be screened and treated for any iron deficiency at booking, 24–28 weeks and 32–34 weeks. Blood transfusion requirements align with recommendations for non-pregnant wAIHA patients, including the additional requirement of CMV seronegative fresh blood components.” 

However, there were important differences to be aware of when it came to the corticosteroid and monoclonal antibody treatments. 

“Steroid exposure should always be minimised where possible. Initial doses of steroids can be lower (20–75mg/day) and tapered as soon as possible to minimise the risk of obstetric complications,” said the authors. 

“[And] rituximab should be avoided in the second and third trimesters of pregnancy as it is actively taken up across the placenta, potentially affecting the fetus. Ideally, rituximab therapy should be completed at least six months prior to conception to ensure maternal immune reconstitution.” 

The authors concluded by acknowledging that AIHA could be a challenging disorder to recognise and treat, but that prompt diagnosis and the use of appropriate management strategies could lead to optimal outcomes for most patients.  

The consensus statement was endorsed by the Haematology Society of Australia and New Zealand, the Australian and New Zealand Society of Blood Transfusion, the Thrombosis and Haemostasis Society of Australia and New Zealand, and consumer representatives convened by ITP Australia and New Zealand.  

Internal Medicine Journal, 8 November 2026 

End of content

No more pages to load

Log In Register ×